Exagen (NASDAQ:XGN – Get Rating) had its target price reduced by KeyCorp from $30.00 to $20.00 in a report issued on Friday, The Fly reports. They currently have an overweight rating on the stock. KeyCorp also issued estimates for Exagen’s FY2024 earnings at ($1.10) EPS. Other analysts have also recently issued reports about the company. […]
Zacks Investment Research cut shares of Exagen (NASDAQ:XGN – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Saturday morning, Zacks.com reports. According to Zacks, “Exagen Inc. is engaged in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases. It developed and […]
Exagen Inc. (NASDAQ:XGN – Get Rating) – Equities researchers at William Blair issued their Q1 2023 earnings per share estimates for shares of Exagen in a report issued on Wednesday, March 23rd. William Blair analyst B. Weinstein expects that the company will earn ($0.51) per share for the quarter. William Blair also issued estimates for […]
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross. | March 22, 2022